Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant estramustine plus LHRH before radical prostatectomy in high-risk prostate cancer
ChiCTR1900023915Phase 4Not yet recruiting
- Sponsor
- Department of Urology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2019
- Modality
- Peptides, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estramustine and gonadorelin in prostate cancer (PCa) (2 arms), sponsored by Department of Urology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Biochemical recurrence-free survival at 1 year and Biochemical recurrence-free survival at 2 years. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
estramustinegonadorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR1900023915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023915.